High-risk carotid endarterectomy

Geza Mozes1

  • 1Division of Vascular Surgery, Mayo Clinic and Mayo Medical School, Rochester, MN 55905, USA. mozes.geza@mayo.edu

Insights

Most "high-risk" carotid endarterectomy (CEA) patients can undergo the procedure safely. Age alone is not a high-risk factor, but specific conditions like prior radiation increase risks.

Area of Science:

  • Vascular Surgery
  • Cerebrovascular Disease Management

Background:

  • Defining
  • high-risk
  • carotid endarterectomy (CEA) is crucial for patient selection and optimizing outcomes.
  • Previous randomized controlled trials (RCTs) excluded many patients, leading to a potentially narrow definition of high-risk cases.

Purpose of the Study:

  • To critically evaluate the concept of
  • high-risk
  • CEA by reviewing diverse evidence.
  • To identify specific risk factors that genuinely increase perioperative morbidity and mortality during CEA.
  • To inform appropriate patient selection for CEA and alternative interventions like carotid artery stenting (CAS).

Main Methods:

  • Comprehensive literature review encompassing controlled randomized trials, retrospective population-based studies, large institution-based studies, and case series.
  • Analysis of evidence regarding the impact of various patient characteristics and clinical scenarios on CEA outcomes.

Main Results:

  • CEA can be safely performed in most patients previously considered
  • high-risk
  • , with low mortality and morbidity.
  • Age (≥80 years) alone is not a significant high-risk criterion.
  • Factors associated with slightly increased risk include contralateral carotid occlusion, carotid reoperation, and CEA after cervical radiation therapy.

Conclusions:

  • The broad exclusion criteria from early CEA trials do not justify a restrictive approach to
  • high-risk
  • patients.
  • Specific individual risk factors, such as prior radiation or reoperation, warrant careful consideration.
  • Carotid artery stenting (CAS) should be reserved for well-defined high-risk patients due to limited evidence on its long-term efficacy compared to CEA.